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Abstract Tripeptidyl-peptidase II (TPP II) is an exopeptidase 
with a remarkably high native Mr ( > 10
6). Recently, an 
alternatively spliced, murine cDNA variant was identified which 
contains an additional 39 bp, encoding 13 aniino acids in the C-
terminal end of the protein. The two enzyme variants were 
expressed in human kidney 293 cells. Both types of subunit were 
found to form the active oligomers. In addition, subunits 
containing the extra 13 amino acids formed an even larger 
complex eluting in the void volume of a Sepharose CL-4B 
column. Thus, it appears that this sequence is important for 
aggregation of subunits. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Tripeptidyl-peptidase II (TPP II) (EC 3.4.14.10) removes 
tripeptides from a free N-terminus of longer peptides [1,2]. 
It has a neutral p H opt imum and a high molecular mass 
(138 k D a for the subunit and > 106 D a for the native en-
zyme) [1,2]. The enzyme has a widespread distribution and has 
been found in the cytoplasm of cells from a number of differ-
ent tissues and species [2,3]. Recently, a cholecystokinin-inac-
tivating peptidase was purified from rat brain and identified as 
a membrane-bound variant of T P P II [4]. 
The cDNAs encoding the human and murine enzymes have 
been cloned and the N-terminal part of the enzyme shown to 
be similar to serine peptidases of the subtilisin-type [5-7]. The 
function of the remainder of the large subunit is not known. 
Recently, a splicing variant of the enzyme was identified, 
which contains an additional 39 bp, encoding the amino acids 
G Q S A A K R Q G K F K K in the C-terminal region [7]. The 
present paper describes the development of an expression sys-
tem and its use in an investigation of the functional impor-
tance of the 13 amino acids which result from alternative 
splicing. 
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Abbreviations: DMEM, Dulbecco's modified Eagle's medium; DTT, 
dithiothreitol; GPI, glycosyl phosphatidylinositol; PLC, phosphoino-
sitol phospholipase C from B. cereus; pNA, />-nitroanilide; TPP II, 
tripeptidyl-peptidase II. 
2. Materials and methods 
2.1. Preparation of constructs 
Murine full-length clones, with (m(+)TPP) or without (m(-)TPP) 
the extra 39 bp [7], were constructed in pUC19 [8] from different 
clones [7] by sequential subcloning [9] (Fig. 1). The construct was 
partially sequenced to ensure that the cloning sites were intact. Besides 
the complete coding sequence, the constructs also encompass 29 bp of 
the untranslated 5'-end and 132 bp or 140 bp of the untranslated 3'-
end. The 3.9 kb EcoRl fragments were cloned into the pcDNA 3 
expression vector (Invitrogen). Clones with the insert in both sense 
and antisense directions were selected and purified. 
2.2. Cells and transfection 
The human embryonic kidney cell line 293 (ATCC CRL 1573) was 
maintained in DMEM with 10% heat-inactivated fetal calf serum, 100 
U/ml penicillin and 100 ug/ml streptomycin, at 37°C in a humidified 
5% C0 2 atmosphere. Transfection of plasmids into the cells was per-
formed by the calcium phosphate precipitation method [10]. For tran-
sient expression of the recombinant protein, 10 ug DNA was used for 
transfection of 1 X 106 cells in a 60 mm culture dish. The cells were 
harvested and used for Western blot and activity measurements 2 days 
after transfection. 
For permanent expression of recombinant protein, the 293 cells 
were transfected with 3 (ig of plasmid DNA. After 2 days, transfected 
cells were trypsinized and transferred to two 10-cm culture dishes. 
Stable transformants were selected and picked after growing the cells 
for 10-14 days in DMEM/F-12 with 10% fetal calf serum and 600 ug/ 
ml of Geneticin (G418, Life Technologies, Ltd). 
2.3. Preparation of cell extracts 
For TPP II-activity measurements and Western blot analysis 5-
10X106 cells were lysed in 50 mM Tris buffer, pH 7.5, containing 
1% Triton X-100, 100 uM bestatin (Sigma), 2 mM EDTA and 50 ug/ 
ml soybean trypsin inhibitor (Sigma) (100 ul/106 cells). Bestatin was 
included in order to ensure that the substrate was not attacked by 
aminopeptidases, whereas the other peptidase inhibitors were included 
for protection of TPP II in the extracts. The cell extracts were imme-
diately centrifuged for 30 min at 14 500 Xg at 4°C and the supernatant 
was collected and diluted 10-fold in 100 mM potassium phosphate 
buffer, pH 7.5, containing 30% glycerol and 1 mM DTT. Under these 
conditions the activity appeared to be stable for at least 1 week at 
4°C, but did not withstand freezing at —20°C. 
2.4. TPP II-activity measurements 
For activity measurements, 100 ul of the diluted cell extracts (cor-
responding to about 10° cells) were incubated with 0.2 mM Ala-Ala-
Phe-pNA (Bachem) in 0.1 M potassium phosphate buffer, pH 7.5, 
containing 15% glycerol and 2.5 mM DTT at 37°C, in a total volume 
of 200 ul. The change in absorbance at 405 nm was measured in an 
ELISA plate reader Multiscan PLUS (Labsystems). 
Protein concentration was measured using the modified Bradford 
method [11,12] with BSA as standard. 
2.5. Western blot analysis 
Sample buffer was added to the diluted cell extracts (corresponding 
to about 104 cells) to give final concentrations of 2.3% SDS, 5% fi-
mercaptoethanol and 10% glycerol. The samples were heated for 5 min 
at 95°C before they were loaded onto an 8% polyacrylamide gel. The 
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Fig. 1. Construction of murine full-length clones without (m(—)TPP) or with (m(+)TPP) the extra 39 bp insert. The different clones used for 
the construct are indicated by: (diagonally hatched bars) 5' RACE; (empty bars) N10; (horizontally hatched bars) K l ; and (vertically hatched 
bars) K8. All clones except K8 have been described previously [7]. Only relevant restriction sites are shown. The inserts were cloned into 
pUC19 in the antisense direction. The numbers of the first and last bp in the constructs correspond to those of the published sequence [7]. 
SDS-PAGE and Western blot analysis were performed essentially as 
described previously [13]. 
2.6. Phosphoinositol phospholipase C treatment of cells 
Intact cell monolayers (5-10 XlO6 in 60-mm dishes) with a high 
expression of m(+)TPP or m(—)TPP were washed with PBS and 
then incubated with PLC from B. cereus (Boehringer Mannheim) (3 
U/ml in 500 ill of PBS, pH 7.4). As a control, cells were also incu-
bated with PBS alone or with 50 mM Tris buffer, pH 7.5, containing 
1% Triton X-100. After incubation for 45 min at 37°C the cells were 
suspended in the original 500 ul of incubation buffer and the cell 
suspension was centrifuged for 30 min at 14500Xg. The enzymatic 
activity in the supernatant was measured as described previously. In 
order to release the remaining TPP II activity, the pellet was dissolved 
in 500 ul 50 mM Tris buffer, pH 7.5, containing 1% Triton X-100, 
centrifuged as reported above, and the activity in the new supernatant 
was measured as described. 
As a positive control, the PLC used was investigated for its ability 
to release alkaline phosphatase from sheep kidney slices. The enzyme 
(at a concentration of 20 mU/ml or 2 U/ml) released as much alkaline 
phosphatase during 1 h at 37°C in the PBS buffer used above as under 
the standard conditions normally applied [14] (data not shown). 
3. Results 
3.1. Control of expression system 
The murine full-length TPP II c D N A with (m(+)TPP) or 
without (m(—)TPP) the extra insert was constructed as de-
scribed in Fig. 1, cloned into the expression vector p c D N A 
3 and used for transfection of human embryonic kidney 293 
cells. Murine c D N A was chosen since the complete extra in-
sert was cloned in this species [7] whereas only part of the 
corresponding human c D N A was cloned [5]. As a control, the 
cells were also transfected with the vector alone. The 293 cells 
have an endogenous expression of TPP II, which is not influ-
enced by the transfection with vector only. Transient expres-
sion of the murine cDNAs showed that both types of subunits 
are active (Fig. 2). Moreover, the cells transformed with the 
antisense variants have as high an endogenous TPP II activity 
as the control cells. 
In addition, stable transformants have been selected. The 
clones with the highest expression of the two subunit types 
showed 7-fold (m( - )TPP-17) and 6-fold (m(+)TPP-21) great-
er activity than control cells, respectively (Table 1). None of 
the high expressing clones showed any obvious phenotypic 
changes with respect to morphology or growth rate. 
3.2. Formation of the active oligomers 
It was previously demonstrated by electron microscopy that 
TPP II is represented by large oligomeric structures, and that 
these structures are a prerequisite for full enzymatic activity 
Fig. 2. Transient expression of murine full-length cDNA with 
(m(+)TPP) or without (m(-)TPP) the extra 39 bp. The cell extracts 
were analysed by Western blotting and for TPP II activity as de-
scribed under Section 2. The activity in the extract from the control 
cells is 0.11 A/I405 min - 1 mg_ 1 protein. 
Table 1 
TPP II activity in extracts from different stable transformants 
Stable transformant 
Control cells 
m(+)TPP-21 
m(+)TPP-ll 
m(+)TPP-14 
m(-)TPP-17 
m(-)TPP-23 
m(-)TPP-5 
(») 
(9) 
(7) 
(4) 
(3) 
(8) 
(3) 
(4) 
Activity ± S.D. 
(AA405 min
- 1 mg~ 
0.12 ±0.02 
0.78 ±0.21 
0.39±0.16 
0.36 ±0.04 
0.88 ±0.29 
0.79 ±0.41 
0.39±0.17 
1 protein) 
Extracts were prepared and activity measured as described under Sec-
tion 2. (ri) indicates the number of measurements. 
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Fig. 3. Sepharose CL-4B chromatography of extracts from control cells and the high-expressing transformant cells m(+)TPP-ll and m(—)TPP-
5. Extracts from 15-20x10° cells were prepared essentially as described under Section 2 except that the protease inhibitors were omitted and 
that 10 (j.1 of lysis buffer/106 cells was used. The diluted supernatant was loaded onto a Sepharose CL-4B column (1x90 cm) equilibrated and 
eluted with 100 mM potassium phosphate buffer, pH 7.5, containing 30% glycerol and 1 mM DTT. Fractions of 0.9 ml were collected at a 
flow rate of 7 ml/h. The TPP II activity in the fractions was measured as described under Section 2. (□) Activity in control cells; (•) activity 
in m(+)TPP-ll cells; (o) activity in m(-)TPP-5 cells. 
[15]. In order to investigate the degree of formation of the 
oligomers, extracts from control cells and high expressing 
clones were subjected to chromatography on a Sepharose 
CL-4B column (Fig. 3). The active enzyme from the control 
cells was eluted with a K&v value around 0.2, corresponding to 
an MI of about 4X10
6, which is comparable with results 
obtained previously with TPP II from rat liver extract [1] 
and human erythrocytes [2]. In addition to an increase of 
this peak, the subunits containing the 13 extra amino acids 
evidently give rise to a complex which elutes in the void vol-
ume of the column, indicating that the molecular mass is 
> 107, and thus is even larger than the normal 4X106 Da 
oligomers. Clones expressing the murine subunits lacking the 
13 amino acids do not contain the large complex (Fig. 3). 
However, it is interesting to note that the control cells show 
a small, but reproducible, activity shoulder eluting in the void 
volume of the column. The immunoreactivity co-eluted with 
the activity, indicating that the main part of the protein is 
active (data not shown). Similar chromatographic profiles 
were obtained for each of two other high-expressing clones 
of m(+)TPP and m(-)TPP (data not shown). 
The void-eluting complex is stable, i.e. the activity persists 
for at least 1 week at 4°C and elutes at the same position if 
rechromatographed on a Sepharose CL-4B column. However, 
the material is less stable after rechromatography. 
3.3. Phospholipase C treatment 
It was suggested by Rose et al. [4] that a splicing variant of 
TPP II could be membrane bound through a glycosyl phos-
phatidylinositol (GPI) anchor. Phospholipase C (PLC) from 
B. cereus can cleave such linkages [16] and was shown to 
release TPP II from synaptosomal membranes [4]. To deter-
mine whether the m(+)TPP splicing variant described here 
could be involved in membrane binding, the ability of PLC 
to release TPP II from cells with a high expression of 
m(+)TPP and m(—)TPP, respectively, was compared (Table 
2). Evidently, no enzymatic activity could be released from 
either cells through this treatment, not even if the cells were 
incubated with 5 U of PLC for 4 h at 37°C (data not shown). 
The PLC used was active, as demonstrated by its ability to 
release alkaline phosphatase from sheep kidney slices, as de-
scribed under Section 2. 
4. Discussion 
This paper describes the expression of murine TPP II in 293 
Table 2 
Effect of PLC treatment of intact cells 
Treatment 
PBS only 
PBS+PLC 
Tris buffer+Triton X-100 
Cells 
m(+)TPP 
m(-)TPP 
m(+)TPP 
m(-)TPP 
m(+)TPP 
m(-)TPP 
Released activity 
(A^405 
0.09 
0.12 
0.05 
0.06 
0.74 
1.02 
mm 1 mg-1) 
Remaining activity 
(A^405 
0.70 
1.07 
0.76 
1.04 
0.06 
0.05 
mm 1 mg"1) 
Released activity 
(%) 
11 
10 
6 
5 
92 
95 
Conditions are described under Section 2. The data represent one experiment out of three. Two different batches of PLC were used in the 
experiments. 
280 B. Tomkinson et al.lFEBS Letters 405 (1997) 277-280 
Table 3 
KEKE motif in TPP II compared with proteasome associated proteins 
m(+)TPP 
REGULATOR 
EROTEASCME C9 
EROTEASCME 2 8 . 1 
26S SLBUNTT 12 
. KKAGOSAAKROGKFXKDVIFVHYYLIPP 
. . . . KKKKKKKRKKQQEKE33KDEKKKUKLlh:i )K 
. . . TTKH kWkMATTAiiiR'EKTnrRWQTTirKTTK 
. . . KT I UKRKHWMI JgKKTCQFT , 
. . . Tglfing3QiKirigRfiKKTTRTniTlinglCT1K I )K KKgTHTKKTnrKTC 
A KEKE motif (bold-face) is defined as more than 12 amino acids in length, devoid of W, Y, F, or P, where more than 60% of the amino 
acids are K or E/D, and where five positive or negatively charged residues do not occur in a row [18]. The TPP II sequence is from [7] and the 
proteasome sequences from [18]. The extra 13 amino acids which are subject to alternative splicing are underlined. 
cells. Stable clones with a 3-7-fold higher enzymatic activity 
than that endogenously expressed have been isolated. Evi-
dently, the over-expression is not lethal to the cells. This could 
indicate that the enzymatic activity can be regulated in the 
cells or that the substrate specificity of the enzyme, even 
though it is fairly broad [1,2], is still restrictive enough to 
prevent T P P II from damaging proteins or peptides in the 
cell. The establishment of an expression system for the enzyme 
is of great importance for further studies of structure-function 
relationships for T P P II. 
It is demonstrated that the extra 13 amino acids, which 
result from alternative splicing, are involved in formation of 
a larger complex (Fig. 3). Whether the extra amino acids are 
important for aggregation of the subunits, or for the forma-
tion of complexes with other proteins or other cellular com-
ponents, is not known. Neither is it known if the larger com-
plex is functionally different. This will be the subject of future 
investigations. That the large complexes, eluting in the void 
volume of a Sepharose CL-4B column, are not artefacts is 
supported by three facts. Firstly, the same peak was seen in 
the analysis of three different, stable transformants expressing 
high levels of m(+)TPP. Secondly, there was a small activity 
shoulder in this position when the control cells were analyzed. 
Thirdly, a similar high-molecular weight activity shoulder is 
seen in the Sepharose CL-4B chromatogram when T P P II is 
purified from human erythrocytes (cf. Fig. 1 in [2]). It could 
be speculated that when both types of subunit are expressed at 
the same time, more of the normal oligomers and less of the 
high molecular weight complex are formed. Preliminary data 
from experiments with stable transformants which express 
both types of subunit simultaneously corroborate this (B. 
Tomkinson, unpublished). 
The sequence of T P P II [5,7] reveals a so-called K E K E 
motif [17] on the C-terminal side of the insertion site of the 
extra 13 amino acids (Table 3). It has been suggested that 
these motifs with alternating positively and negatively charged 
amino acids promote protein-protein interactions [17,18] and 
are also involved in Ca 2 + binding [19]. It could be speculated 
that this motif may be involved also in the formation of the 
T P P II oligomers. The effect of the extra 13 amino acids 
( G Q S A A K R Q G K F K K ) could then be to interact with a 
K E K E motif in another protein or on another subunit. Alter-
natively, the insertion of the extra domain could change the 
protein conformation and expose the K E K E motif. The 
understanding of the potential role of this motif will demand 
more extensive protein engineering studies, e.g. removing only 
this par t or changing specific amino acids in this motif. 
Finally, it was investigated whether the high molecular 
weight complex was lipid bound. In a recent publication, 
Rose et al. demonstrated that a membrane associated variant 
of T P P II was involved in the inactivation of cholecystokinin 
[4]. The authors suggested that the enzyme was bound on the 
outside of the plasma membrane by a G P I anchor and that a 
splicing variant of T P P II was involved. However, in the 
present work treatment of intact cells with PLC, which would 
break the GPI anchor [4,16], did not have any effect (Table 2). 
Therefore, the extra 13 amino acids in m(+)TPP does not 
appear to be involved in membrane binding through a GPI 
anchor. 
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